Updates in heart failure: what last year brought to us
暂无分享,去创建一个
[1] M. Hall. National Heart, Lung, and Blood Institute , 2020, The Grants Register 2021.
[2] P. Ponikowski,et al. Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction , 2018, ESC heart failure.
[3] P. Ponikowski,et al. Phrenic nerve stimulation to treat patients with central sleep apnoea and heart failure , 2018, European journal of heart failure.
[4] P. Macdonald,et al. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018. , 2018, Heart, lung & circulation.
[5] R. Carter,et al. A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction , 2018, Circulation.
[6] I. Macdougall,et al. Iron deficiency in chronic heart failure: case‐based practical guidance , 2018, ESC heart failure.
[7] S. Solomon,et al. Heart failure with mid‐range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum , 2018, European journal of heart failure.
[8] N. Lamblin,et al. Pulmonary hypertension in chronic heart failure: definitions, advances, and unanswered issues , 2018, ESC heart failure.
[9] I. Anand,et al. Anemia and Iron Deficiency in Heart Failure: Current Concepts and Emerging Therapies , 2018, Circulation.
[10] G. Filippatos,et al. Comprehensive in‐hospital monitoring in acute heart failure: applications for clinical practice and future directions for research. A statement from the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) , 2018, European journal of heart failure.
[11] Christopher J. Rush,et al. Effect of digoxin in patients with heart failure and mid‐range (borderline) left ventricular ejection fraction , 2018, European journal of heart failure.
[12] S. Anker,et al. Cancer and heart failure—more than meets the eye: common risk factors and co‐morbidities , 2018, European journal of heart failure.
[13] J. Brachmann,et al. Safety and feasibility of pulmonary artery pressure-guided heart failure therapy: rationale and design of the prospective CardioMEMS Monitoring Study for Heart Failure (MEMS-HF) , 2018, Clinical Research in Cardiology.
[14] Y. Pinto,et al. NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure: PRIMA II Randomized Controlled Trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?) , 2018, Circulation.
[15] F. Gustafsson,et al. Characteristics and long‐term prognosis of patients with heart failure and mid‐range ejection fraction compared with reduced and preserved ejection fraction: a systematic review and meta‐analysis , 2018, ESC heart failure.
[16] James W Long,et al. Two‐Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure , 2018, The New England journal of medicine.
[17] M. B. Bacchi Reggiani,et al. Pulmonary hypertension due to left heart disease: analysis of survival according to the haemodynamic classification of the 2015 ESC/ERS guidelines and insights for future changes , 2018, European journal of heart failure.
[18] Sanjiv J. Shah,et al. Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): A Phase 2, Randomized, Sham-Controlled Trial. , 2017, Circulation.
[19] L. Tavazzi,et al. Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis , 2018, Circulation.
[20] Sanjiv J. Shah,et al. Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology , 2018, European journal of heart failure.
[21] L. Lund,et al. Screening for heart transplantation and left ventricular assist system: results from the ScrEEning for advanced Heart Failure treatment (SEE‐HF) study , 2018, European journal of heart failure.
[22] A. Mebazaa,et al. Characteristics, treatments and 1‐year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long‐Term Registry , 2018, European journal of heart failure.
[23] K. Dickstein,et al. Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes , 2017, European journal of heart failure.
[24] A. Rigby,et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials , 2018, European heart journal.
[25] Sanjiv J. Shah,et al. Impact of atrial fibrillation on rest and exercise haemodynamics in heart failure with mid‐range and preserved ejection fraction , 2017, European journal of heart failure.
[26] P. Ponikowski,et al. What have we learned about heart failure with mid‐range ejection fraction one year after its introduction? , 2017, European journal of heart failure.
[27] L. Lund,et al. Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid‐range, and reduced ejection fraction , 2017, European journal of heart failure.
[28] M. Rienstra,et al. Echocardiographic estimation of left ventricular and pulmonary pressures in patients with heart failure and preserved ejection fraction: a study utilizing simultaneous echocardiography and invasive measurements , 2017, European journal of heart failure.
[29] G. Felker,et al. Diuretic Treatment in Heart Failure. , 2017, The New England journal of medicine.
[30] Robert C. Hendel,et al. Dose Comparison Study of Allogeneic Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy (The TRIDENT Study) , 2017, Circulation research.
[31] M. Giacca,et al. Acylated ghrelin treatment normalizes skeletal muscle mitochondrial oxidative capacity and AKT phosphorylation in rat chronic heart failure , 2017, Journal of cachexia, sarcopenia and muscle.
[32] P. Ponikowski,et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo‐controlled trial , 2017, European journal of heart failure.
[33] S. Anker,et al. Muscle wasting and sarcopenia in heart failure and beyond: update 2017 , 2017, ESC heart failure.
[34] S. Connolly,et al. Comparative effectiveness of transitional care services in patients discharged from the hospital with heart failure: a systematic review and network meta‐analysis , 2017, European journal of heart failure.
[35] G. Filippatos,et al. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long‐Term Registry , 2017, European journal of heart failure.
[36] P. Ponikowski,et al. Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT‐CHF , 2017, European journal of heart failure.
[37] J. Gorcsan,et al. Left ventricular‐only pacing in heart failure patients with normal atrioventricular conduction improves global function and left ventricular regional mechanics compared with biventricular pacing: an adaptive cardiac resynchronization therapy sub‐study , 2017, European journal of heart failure.
[38] S. Anker,et al. Anorexia, functional capacity, and clinical outcome in patients with chronic heart failure: results from the Studies Investigating Co‐morbidities Aggravating Heart Failure (SICA‐HF) , 2017, ESC Heart Failure.
[39] Michael Böhm,et al. The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology , 2017, European journal of heart failure.
[40] Amit N. Patel,et al. Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure , 2017, Circulation research.
[41] Gianluigi Savarese,et al. A comprehensive population‐based characterization of heart failure with mid‐range ejection fraction , 2017, European journal of heart failure.
[42] M. Rienstra,et al. Atrial fibrillation modifies the association between pulmonary artery wedge pressure and left ventricular end‐diastolic pressure , 2017, European journal of heart failure.
[43] K. Anstrom,et al. Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial , 2017, JAMA cardiology.
[44] L. Lund,et al. Association between enrolment in a heart failure quality registry and subsequent mortality—a nationwide cohort study , 2017, European journal of heart failure.
[45] H. D. den Ruijter,et al. The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart failure and a preserved vs. reduced ejection fraction , 2017, European journal of heart failure.
[46] Sanjiv J. Shah,et al. The potential role and rationale for treatment of heart failure with sodium–glucose co‐transporter 2 inhibitors , 2017, European journal of heart failure.
[47] K. Anstrom,et al. Effect of Natriuretic Peptide–Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial , 2017, JAMA.
[48] Gerasimos S Filippatos,et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. , 2017, Journal of the American College of Cardiology.
[49] L. Mimish,et al. Worsening heart failure in ‘real‐world’ clinical practice: predictors and prognostic impact , 2017, European journal of heart failure.
[50] J. Daubert,et al. Predictors of short‐term clinical response to cardiac resynchronization therapy , 2017, European journal of heart failure.
[51] P. Ponikowski,et al. A multimarker multi‐time point‐based risk stratification strategy in acute heart failure: results from the RELAX‐AHF trial , 2017, European journal of heart failure.
[52] K. Anstrom,et al. Palliative Care in Heart Failure: The PAL-HF Randomized, Controlled Clinical Trial. , 2017, Journal of the American College of Cardiology.
[53] Hideaki Shimizu,et al. Impact of chronic kidney disease on the diuretic response of tolvaptan in acute decompensated heart failure , 2017, ESC heart failure.
[54] T. Seidler,et al. A Phase 2a dose‐escalation study of the safety, tolerability, pharmacokinetics and haemodynamic effects of BMS‐986231 in hospitalized patients with heart failure with reduced ejection fraction , 2017, European journal of heart failure.
[55] S. Solomon,et al. Declining Risk of Sudden Death in Heart Failure , 2017, The New England journal of medicine.
[56] V. Melenovský,et al. Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction , 2017, Circulation.
[57] W. Doehner,et al. Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany , 2017, ESC heart failure.
[58] F. Ruschitzka,et al. Prognostic value of long‐term blood pressure changes in patients with chronic heart failure , 2017, European journal of heart failure.
[59] M. Guazzi,et al. Different correlates but similar prognostic implications for right ventricular dysfunction in heart failure patients with reduced or preserved ejection fraction , 2017, European journal of heart failure.
[60] M. Senni,et al. Prediction of right ventricular failure after ventricular assist device implant: systematic review and meta‐analysis of observational studies , 2017, European journal of heart failure.
[61] Akshay S. Desai,et al. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. , 2017, JACC. Heart failure.
[62] P. Ponikowski,et al. A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure , 2017, European journal of heart failure.
[63] P. Ponikowski,et al. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study , 2017, European heart journal.
[64] K. Swedberg,et al. Heart rate and its reduction in chronic heart failure and beyond , 2017, European journal of heart failure.
[65] P. Ponikowski,et al. Plasma biomarkers to predict or rule out early post-discharge events in patients discharged after an acute heart failure hospital admission , 2017 .
[66] C. O'connor,et al. Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure—does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies (VERITAS) , 2017, European journal of heart failure.
[67] S. Solomon,et al. Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia , 2017, European journal of heart failure.
[68] P. Ponikowski,et al. Urinary levels of novel kidney biomarkers and risk of true worsening renal function and mortality in patients with acute heart failure , 2017, European journal of heart failure.
[69] P. Ponikowski,et al. Patient‐reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES‐PRESERVED) study , 2017, European journal of heart failure.
[70] L. Lund,et al. Significance of Ischemic Heart Disease in Patients With Heart Failure and Preserved, Midrange, and Reduced Ejection Fraction: A Nationwide Cohort Study , 2017, Circulation. Heart failure.
[71] B. Gersh,et al. Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART‐1) study , 2017, European journal of heart failure.
[72] S. Anker,et al. Emphasis on abdominal obesity as a modifier of eplerenone effect in heart failure: hypothesis‐generating signals from EMPHASIS‐HF , 2017, European journal of heart failure.
[73] Timothy S. Phan,et al. Effects of organic and inorganic nitrate on aortic and carotid haemodynamics in heart failure with preserved ejection fraction , 2017, European journal of heart failure.
[74] Akshay S. Desai,et al. Ambulatory Hemodynamic Monitoring Reduces Heart Failure Hospitalizations in "Real-World" Clinical Practice. , 2017, Journal of the American College of Cardiology.
[75] G. Fonarow,et al. Extracorporeal Ultrafiltration for Fluid Overload in Heart Failure , 2017, Journal of the American College of Cardiology.
[76] I. Buchan,et al. Do patients have worse outcomes in heart failure than in cancer? A primary care‐based cohort study with 10‐year follow‐up in Scotland , 2017, European journal of heart failure.
[77] P. Ponikowski,et al. Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure , 2017, European journal of heart failure.
[78] J. Maessen,et al. Modalities and Effects of Left Ventricle Unloading on Extracorporeal Life support: a Review of the Current Literature , 2017, European journal of heart failure.
[79] Sanjiv J. Shah,et al. INDIE-HFpEF (Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure With Preserved Ejection Fraction): Rationale and Design. , 2017, Circulation. Heart failure.
[80] Finn Gustafsson,et al. Left ventricular assist device therapy in advanced heart failure: patient selection and outcomes , 2017, European journal of heart failure.
[81] P. Ponikowski,et al. Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry , 2017, European journal of heart failure.
[82] Gerasimos S Filippatos,et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. , 2017, Journal of cardiac failure.
[83] J. Morley. Anorexia of ageing: a key component in the pathogenesis of both sarcopenia and cachexia , 2017, Journal of cachexia, sarcopenia and muscle.
[84] R. Kronmal,et al. High-Sensitive Cardiac Troponin T as an Early Biochemical Signature for Clinical and Subclinical Heart Failure: MESA (Multi-Ethnic Study of Atherosclerosis) , 2017, Circulation.
[85] P. Ponikowski,et al. Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure , 2017, The New England journal of medicine.
[86] M. Komajda,et al. Brain natriuretic peptide usefulness in very elderly dyspnoeic patients: the BED study , 2017, European journal of heart failure.
[87] S. Solomon,et al. Influence of atrial fibrillation on post‐discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial , 2017, European journal of heart failure.
[88] R. Wachter,et al. Heart failure awareness survey in Germany: general knowledge on heart failure remains poor , 2017, ESC heart failure.
[89] J. Massaro,et al. Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload. , 2017, Journal of the American College of Cardiology.
[90] J. McMurray,et al. Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS‐HF trial , 2017, European journal of heart failure.
[91] J. Cleland,et al. The effects of short‐term omission of daily medication on the pathophysiology of heart failure , 2017, European journal of heart failure.
[92] P. Ponikowski,et al. Carotid body resection for sympathetic modulation in systolic heart failure: results from first‐in‐man study , 2017, European journal of heart failure.
[93] S. Blankenberg,et al. Concomitant implantation of Impella® on top of veno‐arterial extracorporeal membrane oxygenation may improve survival of patients with cardiogenic shock , 2017, European journal of heart failure.
[94] G. Filippatos,et al. European Society of Cardiology Heart Failure Long‐Term Registry (ESC‐HF‐LT): 1‐year follow‐up outcomes and differences across regions , 2016, European journal of heart failure.
[95] K. Domschke,et al. A functional variant of the neuropeptide S receptor‐1 gene modulates clinical outcomes and healthcare utilization in patients with systolic heart failure: results from the Interdisciplinary Network Heart Failure (INH) Study , 2017, European journal of heart failure.
[96] Jeroen J. Bax,et al. Myocardial strain to detect subtle left ventricular systolic dysfunction , 2017, European journal of heart failure.
[97] P. Ponikowski,et al. Plasma biomarkers to predict or rule out early post‐discharge events after hospitalization for acute heart failure , 2017, European journal of heart failure.
[98] Haran Burri,et al. Effects of remote monitoring on clinical outcomes and use of healthcare resources in heart failure patients with biventricular defibrillators: results of the MORE‐CARE multicentre randomized controlled trial , 2017, European journal of heart failure.
[99] L. Lund,et al. Registry-Based Pragmatic Trials in Heart Failure: Current Experience and Future Directions , 2017, Current Heart Failure Reports.
[100] J. Cleland,et al. What proportion of patients with chronic heart failure are eligible for sacubitril–valsartan? , 2017, European journal of heart failure.
[101] G. Kundt,et al. Stem cell registry programme for patients with ischemic cardiomyopathy undergoing coronary artery bypass grafting: what benefits does it derive? , 2017, ESC heart failure.
[102] L. Lund,et al. Association between demographic, organizational, clinical, and socio‐economic characteristics and underutilization of cardiac resynchronization therapy: results from the Swedish Heart Failure Registry , 2017, European journal of heart failure.
[103] Gregory A. Ewald,et al. A Fully Magnetically Levitated Circulatory Pump for Advanced Heart Failure , 2017, The New England journal of medicine.
[104] A. Mebazaa,et al. Agents with vasodilator properties in acute heart failure. , 2017, European heart journal.
[105] J. McMurray,et al. Insufficient reduction in heart rate during hospitalization despite beta‐blocker treatment in acute decompensated heart failure: insights from the ASCEND‐HF trial , 2017, European journal of heart failure.
[106] K. Rentsch,et al. Impact of haemoconcentration during acute heart failure therapy on mortality and its relationship with worsening renal function , 2017, European journal of heart failure.
[107] A. Cohen-Solal,et al. Precipitating factors and 90‐day outcome of acute heart failure: a report from the intercontinental GREAT registry , 2017, European journal of heart failure.
[108] K. Dickstein,et al. Association of beta‐blocker treatment with mortality following myocardial infarction in patients with chronic obstructive pulmonary disease and heart failure or left ventricular dysfunction: a propensity matched‐cohort analysis from the High‐Risk Myocardial Infarction Database Initiative , 2017, European journal of heart failure.
[109] E. Mathiesen,et al. Uric acid predicts mortality and ischaemic stroke in subjects with diastolic dysfunction: the Tromsø Study 1994–2013 , 2017, ESC heart failure.
[110] D. Ellison,et al. Renal tubular resistance is the primary driver for loop diuretic resistance in acute heart failure , 2017, European journal of heart failure.
[111] J. Gavira,et al. Benefit of tolvaptan in the management of hyponatraemia in patients with diuretic‐refractory congestive heart failure: the SEMI‐SEC project , 2017, ESC heart failure.
[112] L. Køber,et al. ICD Implantation in Patients with Nonischemic Heart Failure. , 2017, The New England journal of medicine.
[113] L. Fauchier,et al. ICD Implantation in Patients with Nonischemic Heart Failure. , 2017, The New England journal of medicine.
[114] L. Lund,et al. Determinants and prognostic implications of the negative diastolic pulmonary pressure gradient in patients with pulmonary hypertension due to left heart disease , 2017, European journal of heart failure.
[115] D. Fitchett,et al. Heart failure outcomes in clinical trials of glucose‐lowering agents in patients with diabetes , 2017, European journal of heart failure.
[116] A. Voors,et al. Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health‐related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension , 2017, European journal of heart failure.
[117] L. Tarnow,et al. Effect of liraglutide, a glucagon‐like peptide‐1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double‐blind, randomised, placebo‐controlled trial , 2017, European journal of heart failure.
[118] S. Grajek,et al. Safety, feasibility and effectiveness of first in‐human administration of muscle‐derived stem/progenitor cells modified with connexin‐43 gene for treatment of advanced chronic heart failure , 2017, European journal of heart failure.
[119] J. Beattie,et al. Palliative care in heart failure: facts and numbers , 2016, ESC heart failure.
[120] B. Gersh,et al. Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial , 2016, European heart journal.
[121] Takeshi Kimura,et al. Dynamic changes of serum microRNA‐122‐5p through therapeutic courses indicates amelioration of acute liver injury accompanied by acute cardiac decompensation , 2016, ESC heart failure.
[122] M. Parmar,et al. An exploratory randomized control study of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with ischaemic cardiomyopathy: the REGENERATE‐IHD clinical trial , 2016, European journal of heart failure.
[123] C. Hsiung,et al. Integrated care for geriatric frailty and sarcopenia: a randomized control trial , 2016, Journal of cachexia, sarcopenia and muscle.
[124] K. Anstrom,et al. Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial , 2017, European journal of heart failure.
[125] Amit N. Patel,et al. Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure: A Phase 1/2 Randomized Controlled Trial (RIMECARD Trial) , 2017 .
[126] V. Melenovský,et al. The Role of Diastolic Stress Testing in the Evaluation for HFpEF : A Simultaneous Invasive-Echocardiographic Study , 2016 .
[127] W. Haverkamp,et al. Resting heart rate is an independent predictor of death in patients with colorectal, pancreatic, and non‐small cell lung cancer: results of a prospective cardiovascular long‐term study , 2016, European journal of heart failure.
[128] S. Solomon,et al. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM‐study programme , 2016, European journal of heart failure.
[129] P. Ponikowski,et al. One-Year Outcomes After Transcatheter Insertion of an Interatrial Shunt Device for the Management of Heart Failure With Preserved Ejection Fraction , 2016, Circulation. Heart failure.
[130] S. Anker,et al. Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016 , 2016, Journal of cachexia, sarcopenia and muscle.
[131] A. Jaffe,et al. Biomarker‐based risk prediction in the community , 2016, European journal of heart failure.
[132] T. Marwick,et al. Echocardiographic screening for non‐ischaemic stage B heart failure in the community , 2016, European journal of heart failure.
[133] P. Ponikowski,et al. Transvenous stimulation of the phrenic nerve for the treatment of central sleep apnoea: 12 months' experience with the remedē® System , 2016, European journal of heart failure.
[134] E. Keeley,et al. Obesity paradox in heart failure: a heavy matter , 2016, ESC heart failure.
[135] M. Packer. Kicking the tyres of a heart failure trial: physician response to the approval of sacubitril/valsartan in the USA , 2016, European journal of heart failure.
[136] A. Voors,et al. Right ventricular dysfunction in heart failure with preserved ejection fraction: a systematic review and meta‐analysis , 2016, European journal of heart failure.
[137] S. Ghio,et al. Right ventricular recovery during follow‐up is associated with improved survival in patients with chronic heart failure with reduced ejection fraction , 2016, European journal of heart failure.
[138] I. Eržen,et al. National trends in heart failure hospitalization rates in Slovenia 2004–2012 , 2016, European journal of heart failure.
[139] K. Anstrom,et al. Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. , 2016, JAMA.
[140] S. Anker,et al. Heart failure epidemiology and novel treatments in Japan: facts and numbers , 2016, ESC heart failure.
[141] R. Wachter,et al. Heart failure epidemiology 2000–2013: insights from the German Federal Health Monitoring System , 2016, European journal of heart failure.
[142] Piotr Ponikowski,et al. Patient journey after admission for acute heart failure: length of stay, 30‐day readmission and 90‐day mortality , 2016, European journal of heart failure.
[143] V. Melenovský,et al. Inhaled Sodium Nitrite Improves Rest and Exercise Hemodynamics in Heart Failure With Preserved Ejection Fraction. , 2016, Circulation research.
[144] R. Clark,et al. Characteristics of patients with haematological and breast cancer (1996–2009) who died of heart failure‐related causes after cancer therapy , 2016, ESC heart failure.
[145] S. Hoshida,et al. Age‐ and sex‐related differences in diastolic function and cardiac dimensions in a hypertensive population , 2016, ESC heart failure.
[146] D. Mele,et al. Cardiac resynchronization therapy guided by multimodality cardiac imaging , 2016, European journal of heart failure.
[147] P. Ponikowski,et al. Effects of intravenous iron therapy in iron‐deficient patients with systolic heart failure: a meta‐analysis of randomized controlled trials , 2016, European journal of heart failure.
[148] G. Filippatos,et al. Body surface area as a prognostic marker in chronic heart failure patients: results from the Heart Failure Registry of the Heart Failure Association of the European Society of Cardiology , 2016, European journal of heart failure.
[149] S. Anker,et al. Systematic review and meta‐analysis of iron therapy in anaemic adults without chronic kidney disease: updated and abridged Cochrane review , 2016, European journal of heart failure.
[150] P. Ponikowski,et al. The influence of iron deficiency on the functioning of skeletal muscles: experimental evidence and clinical implications , 2016, European journal of heart failure.
[151] H. Bueno,et al. Prevalence and prognostic impact of frailty and its components in non‐dependent elderly patients with heart failure , 2016, European journal of heart failure.
[152] G. Filippatos,et al. Reframing the association and significance of co‐morbidities in heart failure , 2016, European journal of heart failure.
[153] John B Buse,et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.
[154] G. Filippatos,et al. European Society of Cardiology Heart Failure Long‐Term Registry (ESC‐HF‐LT): 1‐year follow‐up outcomes and differences across regions , 2016, European journal of heart failure.
[155] P. Ponikowski,et al. Plasma kidney injury molecule‐1 in heart failure: renal mechanisms and clinical outcome , 2016, European journal of heart failure.
[156] P. Ponikowski,et al. Non‐adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT , 2016, European journal of heart failure.
[157] J. Springer,et al. Cardiac cachexia: hic et nunc , 2016, Journal of cachexia, sarcopenia and muscle.
[158] H. Bøtker,et al. Thirty‐year trends in heart failure hospitalization and mortality rates and the prognostic impact of co‐morbidity: a Danish nationwide cohort study , 2016, European journal of heart failure.
[159] K. Sakamoto,et al. Clinical significance of pulse pressure in patients with heart failure with preserved left ventricular ejection fraction , 2016, European journal of heart failure.
[160] Y. Pinto,et al. MicroRNAs in heart failure: from biomarker to target for therapy , 2016, European journal of heart failure.
[161] Jeroen J. Bax,et al. Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency , 2016, European journal of heart failure.
[162] P. Ponikowski,et al. A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT‐CHF , 2016, European journal of heart failure.
[163] P. Ponikowski,et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease , 2016, European heart journal.
[164] J. McMurray,et al. The incremental prognostic and clinical value of multiple novel biomarkers in heart failure , 2016, European journal of heart failure.
[165] M. Roncaglioni,et al. Outcomes in patients hospitalized for heart failure and chronic obstructive pulmonary disease: differences in clinical profile and treatment between 2002 and 2009 , 2016, European journal of heart failure.
[166] J. Jensen,et al. Multimodality imaging‐guided left ventricular lead placement in cardiac resynchronization therapy: a randomized controlled trial , 2016, European journal of heart failure.
[167] M. Cowie,et al. Sleep‐disordered breathing in heart failure , 2016, European journal of heart failure.
[168] P. Ponikowski,et al. Signature of circulating microRNAs in patients with acute heart failure , 2016, European journal of heart failure.
[169] N. Hagiwara,et al. Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure , 2016, ESC heart failure.
[170] P. Pibarot,et al. Unidirectional left-to-right interatrial shunting for treatment of patients with heart failure with reduced ejection fraction: a safety and proof-of-principle cohort study , 2016, The Lancet.
[171] D. Burkhoff,et al. A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial , 2016, The Lancet.
[172] Rami N. Khushaba,et al. Development and validation of a novel non‐contact monitor of nocturnal respiration for identifying sleep‐disordered breathing in patients with heart failure , 2016, ESC heart failure.
[173] P. Ponikowski,et al. Optimizing clinical use of biomarkers in high‐risk acute heart failure patients , 2016, European journal of heart failure.
[174] J. McMurray,et al. Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction , 2016, European journal of heart failure.
[175] F. Rutten,et al. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review , 2016, European journal of heart failure.
[176] V. Kunadian,et al. Direct cellular reprogramming for cardiac repair and regeneration , 2016, European journal of heart failure.
[177] G. Barbati,et al. Early right ventricular response to cardiac resynchronization therapy: impact on clinical outcomes , 2016, European journal of heart failure.
[178] Akshay S. Desai,et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. , 2016, European heart journal.
[179] P. Neužil,et al. Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Systolic Heart Failure: The DEFEAT-HF Study. , 2016, JACC. Heart failure.
[180] Simon Gibbs,et al. 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. , 2016, Revista espanola de cardiologia.
[181] A. Mebazaa,et al. Effect of precipitating factors of acute heart failure on readmission and long‐term mortality , 2016, ESC heart failure.
[182] R. Ristl,et al. The right heart in heart failure with preserved ejection fraction: insights from cardiac magnetic resonance imaging and invasive haemodynamics , 2016, European journal of heart failure.
[183] Y. Takeishi,et al. Associations of dipeptidyl peptidase‐4 inhibitors with mortality in hospitalized heart failure patients with diabetes mellitus , 2015, ESC heart failure.
[184] A. Jaffe,et al. Biomarkers in heart failure: the importance of inconvenient details , 2015, ESC heart failure.
[185] C. Vrints,et al. Adiponectin resistance in skeletal muscle: pathophysiological implications in chronic heart failure , 2015, Journal of cachexia, sarcopenia and muscle.
[186] C. Morgan,et al. Higher risk for incident heart failure and cardiovascular mortality among community‐dwelling octogenarians without pneumococcal vaccination , 2015, ESC heart failure.
[187] Volkmar Falk,et al. 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. , 2016, Revista espanola de cardiologia.
[188] Gabriel A. Koepp,et al. Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. , 2015, The New England journal of medicine.
[189] P. Ponikowski,et al. Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX‐AHF study , 2015, European journal of heart failure.
[190] P. Ponikowski,et al. In‐hospital worsening heart failure , 2015, European journal of heart failure.
[191] V. Melenovský,et al. Sodium Nitrite Improves Exercise Hemodynamics and Ventricular Performance in Heart Failure With Preserved Ejection Fraction. , 2015, Journal of the American College of Cardiology.
[192] M. Pencina,et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. , 2015, The New England journal of medicine.
[193] Hajime Kataoka,et al. Clinical significance of bilateral leg edema and added value of monitoring weight gain during follow‐up of patients with established heart failure , 2015, ESC heart failure.
[194] S. Chaudhry,et al. Burden of Comorbidities and Functional and Cognitive Impairments in Elderly Patients at the Initial Diagnosis of Heart Failure and Their Impact on Total Mortality: The Cardiovascular Health Study. , 2015, JACC. Heart failure.
[195] K. Damman,et al. The kidney in heart failure: an update. , 2015, European heart journal.
[196] Y. Juillière,et al. National trends in rate of patients hospitalized for heart failure and heart failure mortality in France, 2000–2012 , 2015, European journal of heart failure.
[197] R. Wachter,et al. Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction. , 2015, JACC. Heart failure.
[198] W. Cushman,et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial , 2015, The Lancet.
[199] C. Lam. Heart failure in Southeast Asia: facts and numbers , 2015, ESC heart failure.
[200] Akshay S. Desai,et al. Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial , 2015, Circulation.
[201] Akshay S. Desai,et al. Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure , 2015, Circulation.
[202] Thomas P Cappola,et al. The diastolic pulmonary gradient does not predict survival in patients with pulmonary hypertension due to left heart disease. , 2015, JACC. Heart failure.
[203] Piotr Ponikowski,et al. Heart failure: preventing disease and death worldwide , 2014, ESC heart failure.
[204] Milton Packer,et al. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. , 2014, Journal of the American College of Cardiology.
[205] Deepak L. Bhatt,et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. , 2013, The New England journal of medicine.
[206] W. Paulus,et al. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. , 2013, Journal of the American College of Cardiology.
[207] Manesh R. Patel,et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. , 2013, JAMA.
[208] Adrian F Hernandez,et al. Diuretic strategies in patients with acute decompensated heart failure. , 2011, The New England journal of medicine.
[209] Michael Böhm,et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study , 2010, The Lancet.
[210] P. Ponikowski,et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. , 2009, The New England journal of medicine.
[211] S. Katz,et al. Anemia in Chronic Heart Failure: Prevalence, Etiology, Clinical Correlates, and Treatment Options , 2006, Circulation.
[212] T. Vrobel. Psychiatric Aspects of Congestive Heart Failure: Implications for Consulting Psychiatrists , 1990, International journal of psychiatry in medicine.